Figure 2From: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes Impact of AREG mRNA levels on cetuximab-treated patient survival by KRAS tumour mutation. (Blue line: AREG-high, Red line: AREG-low). a) KRAS wild-type (p=0.0005), b) KRAS mutated (p=0.64).Back to article page